Mark R. Silvis

1.7k total citations
19 papers, 1.1k citations indexed

About

Mark R. Silvis is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cell Biology. According to data from OpenAlex, Mark R. Silvis has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cell Biology. Recurrent topics in Mark R. Silvis's work include Melanoma and MAPK Pathways (4 papers), Neonatal Respiratory Health Research (3 papers) and Hippo pathway signaling and YAP/TAZ (3 papers). Mark R. Silvis is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Neonatal Respiratory Health Research (3 papers) and Hippo pathway signaling and YAP/TAZ (3 papers). Mark R. Silvis collaborates with scholars based in United States and United Kingdom. Mark R. Silvis's co-authors include Valeri Vasioukhin, Neil A. Bradbury, Wen‐Hui Lien, Nadia A. Ameen, Olga Klezovitch, Bridget Kreger, Fernando D. Camargo, John T. Seykora, Yuchi Honaker and Sarah T. Arron and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Genes & Development.

In The Last Decade

Mark R. Silvis

17 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Silvis United States	13	662	639	221	134	89	19	1.1k
Yunhua Chang France	19	518 0.8×	239 0.4×	156 0.7×	111 0.8×	94 1.1×	36	1.3k
Claudine Tardy France	12	801 1.2×	358 0.6×	167 0.8×	372 2.8×	173 1.9×	19	1.3k
Cynthia A. Sparks United States	9	912 1.4×	653 1.0×	65 0.3×	137 1.0×	71 0.8×	9	1.3k
Tomoyo Okada Japan	19	837 1.3×	396 0.6×	166 0.8×	166 1.2×	95 1.1×	22	1.3k
V. C. Padmakumar United States	11	1.1k 1.7×	401 0.6×	82 0.4×	151 1.1×	100 1.1×	12	1.4k
Celeste Richardson United States	12	1.2k 1.9×	296 0.5×	87 0.4×	223 1.7×	142 1.6×	16	1.6k
Evan Barry United States	11	891 1.3×	841 1.3×	106 0.5×	240 1.8×	90 1.0×	17	1.4k
Liang‐Yi Hung Taiwan	23	840 1.3×	405 0.6×	135 0.6×	386 2.9×	205 2.3×	55	1.4k
Shinobu Honda Japan	14	677 1.0×	654 1.0×	177 0.8×	333 2.5×	48 0.5×	28	1.1k
Carlo Cosimo Campa Italy	14	748 1.1×	290 0.5×	59 0.3×	94 0.7×	49 0.6×	23	1.1k

Countries citing papers authored by Mark R. Silvis

Since Specialization

Citations

This map shows the geographic impact of Mark R. Silvis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Silvis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Silvis more than expected).

Fields of papers citing papers by Mark R. Silvis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Silvis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Silvis. The network helps show where Mark R. Silvis may publish in the future.

Co-authorship network of co-authors of Mark R. Silvis

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Silvis. A scholar is included among the top collaborators of Mark R. Silvis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Silvis. Mark R. Silvis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Ghazi, Phaedra C., Mark R. Silvis, Yun Zhang, et al.. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 13. 5 indexed citations

Ghazi, Phaedra C., Mark R. Silvis, Yun Zhang, et al.. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 13. 9 indexed citations

Silvis, Mark R., Sophia Schuman, Swapna Aravind Gudipaty, et al.. (2023). Abstract 3861: c-MYC mediated resistance to trametinib plus hydroxychloroquine in pancreatic cancer is overcome by CDK4/6 and lysosomal inhibition. Cancer Research. 83(7_Supplement). 3861–3861.

Silvis, Mark R., Sophia Schuman, Swapna Aravind Gudipaty, et al.. (2023). MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. The Journal of Experimental Medicine. 220(3). 21 indexed citations

Kircher, David A., Mark R. Silvis, Grant M. Fischer, et al.. (2019). AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular Cancer Research. 17(9). 1787–1800. 44 indexed citations

Kinsey, Conan G., et al.. (2019). Abstract C30: Myc amplification is a negative biomarker and a resistance mechanism to trametinib/HCQ treatment, but can be overcome by combined palbociclib/HCQ treatment. Cancer Research. 79(24_Supplement). C30–C30.

Yu, Diana, Mark R. Silvis, James P. Robinson, et al.. (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Reports. 23(5). 1553–1564. 79 indexed citations

Teerlink, Craig C., Chad D. Huff, Jeff Stevens, et al.. (2018). A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. JNCI Journal of the National Cancer Institute. 110(12). 1380–1385. 25 indexed citations

Silvis, Mark R., et al.. (2018). PittGrub. 3 indexed citations

10.

Robinson, James P., Vito W. Rebecca, David A. Kircher, et al.. (2017). Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Research. 27(6). 545–557. 8 indexed citations

11.

Li, Peng, Mark R. Silvis, Yuchi Honaker, et al.. (2016). αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes & Development. 30(7). 798–811. 151 indexed citations

12.

Kircher, David A., Mark R. Silvis, Pauline Cho, & Sheri L. Holmen. (2016). Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. International Journal of Molecular Sciences. 17(9). 1468–1468. 47 indexed citations

13.

Nguyen, Liem T., Maria Tretiakova, Mark R. Silvis, et al.. (2015). ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell. 27(6). 797–808. 94 indexed citations

14.

Butterworth, Michael, Robert S. Edinger, Mark R. Silvis, et al.. (2011). Rab11b regulates the trafficking and recycling of the epithelial sodium channel (ENaC). American Journal of Physiology-Renal Physiology. 302(5). F581–F590. 52 indexed citations

15.

Silvis, Mark R., Bridget Kreger, Wen‐Hui Lien, et al.. (2011). α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1. Science Signaling. 4(174). ra33–ra33. 278 indexed citations

16.

Silvis, Mark R., Carol A. Bertrand, Nadia A. Ameen, et al.. (2009). Rab11b Regulates the Apical Recycling of the Cystic Fibrosis Transmembrane Conductance Regulator in Polarized Intestinal Epithelial Cells. Molecular Biology of the Cell. 20(8). 2337–2350. 100 indexed citations

17.

Oztan, Asli, Mark R. Silvis, Ora A. Weisz, et al.. (2007). Exocyst Requirement for Endocytic Traffic Directed Toward the Apical and Basolateral Poles of Polarized MDCK Cells. Molecular Biology of the Cell. 18(10). 3978–3992. 110 indexed citations

18.

Ameen, Nadia A., Mark R. Silvis, & Neil A. Bradbury. (2006). Endocytic trafficking of CFTR in health and disease. Journal of Cystic Fibrosis. 6(1). 1–14. 82 indexed citations

19.

Silvis, Mark R., et al.. (2003). A Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Generates a Novel Internalization Sequence and Enhances Endocytic Rates. Journal of Biological Chemistry. 278(13). 11554–11560. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact